רינבוק 15 מ"ג - Rinvoq 15 mg: הבדלים בין גרסאות
מתוך ויקיתרופות
| שורה 40: | שורה 40: | ||
|התוויה= | |התוויה= | ||
<div style="direction:ltr;"> | <div style="direction:ltr;"> | ||
| − | Rheumatoid | + | Rheumatoid arthritis RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Psoriatic arthritis RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate. Ankylosing spondylitis RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. Atopic dermatitis RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Ulcerative colitis RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s disease RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.Polyarticular juvenile idiopathic arthritisRINVOQ 15mg tablets is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.Limitations of Use RINVOQ 15 MG is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.Juvenile psoriatic arthritis RINVOQ 15 MG is indicated for the treatment of pediatric patients 2 years of age and older with active juvenile psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.Limitations of Use RINVOQ 15 MG is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine." |
</div> | </div> | ||
|ללא קטגוריה= | |ללא קטגוריה= | ||
|במרשם=כן | |במרשם=כן | ||
|עלון לרופא={{רווח קשיח}} | |עלון לרופא={{רווח קשיח}} | ||
| − | |||
| − | |||
|עלון לצרכן={{רווח קשיח}} | |עלון לצרכן={{רווח קשיח}} | ||
| − | *[ | + | *[[מדיה:Rishum01_20_733899024.pdf|עלון לצרכן עברית 31.12.2024]] |
| − | *[ | + | *[[מדיה:Rishum01_18_628542624.pdf|עלון לצרכן אנגלית - Patient information leaflet{{כ}} 30.09.2024]] |
| − | *[ | + | *[[מדיה:Rishum_21_884062121.pdf|עלון לצרכן ערבית - نشرة للمستهلك باللغة العربية 31.05.2021]] |
| − | *[ | + | *[[מדיה:Rishum01_18_628542824.pdf|עלון לצרכן ערבית - نشرة للمستهلك باللغة العربية 30.09.2024]] |
| − | *[ | + | *[[מדיה:|עלון לרופא 31.12.2024]] |
| + | *[[מדיה:|החמרה לעלון 02.05.2023]] | ||
| + | *[[מדיה:|החמרה לעלון 08.08.2022]] | ||
| + | *[[מדיה:|החמרה לעלון 31.08.2022]] | ||
| + | *[[מדיה:|החמרה לעלון 11.04.2022]] | ||
| + | *[[מדיה:|החמרה לעלון 27.12.2021]] | ||
| + | *[[מדיה:|החמרה לעלון 10.11.2021]] | ||
| + | *[[מדיה:|החמרה לעלון 12.10.2021]] | ||
| + | *[[מדיה:|החמרה לעלון 25.07.2021]] | ||
| + | *[[מדיה:|החמרה לעלון 23.05.2021]] | ||
| + | *[[מדיה:|החמרה לעלון 10.04.2020]] | ||
| + | *[[מדיה:|החמרה לעלון 10.04.2020]] | ||
| + | *[[מדיה:|חוברת מידע בטיחותי לצוות הרפואי אנגלית 30.10.2022]] | ||
| + | *[[מדיה:|כרטיס מידע בטיחותי למטופלים רב שפתי 20.10.2021]] | ||
|החמרות לעלון={{רווח קשיח}} | |החמרות לעלון={{רווח קשיח}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|קבוצה פרמקולוגית (ATC)={{ATC משרד הבריאות|L04AA|Selective immunosuppressants}} | |קבוצה פרמקולוגית (ATC)={{ATC משרד הבריאות|L04AA|Selective immunosuppressants}} | ||
|רישיון מתאריך= | |רישיון מתאריך= | ||
|שיווק הופסק=לא | |שיווק הופסק=לא | ||
| − | |תאריך עדכון= | + | |תאריך עדכון=10/01/2025 |
|התאמת מינון= | |התאמת מינון= | ||
|התוויות נגד= | |התוויות נגד= | ||
גרסה מתאריך 18:03, 10 בינואר 2025
נתוני תרופה
במרשם 
| מינונים נוספים | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| קבוצה פרמקולוגית (ATC4) | L04AA Selective immunosuppressants | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| מרכיב פעיל (ATC5) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
| צורת מתן | פומי - PER OS | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| צורת מינון | טבליות בשחרור ממושך, TABLETS PROLONGED RELEASE למניעת מינון יתר או הרעלה יש ליטול את התרופה בהתאם למינון המומלץ כפי שמופיע בעלון לצרכן | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| התוויה | Rheumatoid arthritis RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Psoriatic arthritis RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate. Ankylosing spondylitis RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. Atopic dermatitis RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Ulcerative colitis RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s disease RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.Polyarticular juvenile idiopathic arthritisRINVOQ 15mg tablets is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.Limitations of Use RINVOQ 15 MG is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.Juvenile psoriatic arthritis RINVOQ 15 MG is indicated for the treatment of pediatric patients 2 years of age and older with active juvenile psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.Limitations of Use RINVOQ 15 MG is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine." | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| עלון לרופא והחמרות לעלון |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
| עלון לצרכן |
|
|---|
| ערכים בוויקירפואה | ערכים קשורים בוויקירפואה |
|---|---|
| רינבוק 15 מ"ג במאגר משרד הבריאות
רינבוק 15 מ"ג במאגר משרד הבריאות |
| חיפוש מאמרים | מאמרים ב-PubMed |
|---|---|
| מידע ברשת | RxList WebMD Drugs.com |
| שם יצרן | ABBVIE DEUTSCHLAND GMBH & CO. KG, GERMANY |
| שם בעל הרישום | ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL |
| רישיון | תאריך הגשה: 7/2019. רישיון מתאריך: |
| תאריך עדכון אחרון | 10/01/2025 |
תמונת אריזה
מאמרים
לצפייה במידע מורחב לרופאים יש להיכנס לחשבונך. אם אינך רשום הכנס להרשמה לרופאים ואנשי מקצועות רפואיים.
